{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.6","upperLimit":"11.8","value":"8.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"OS was defined as the time from the date of first dose to the date of death due to any cause. If a participant was not known to have died, survival time was censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"OG000","title":"Binimetinib (MEK162)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all the participants who had received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of death due to any cause (maximum up to 19.4 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}